XML 27 R16.htm IDEA: XBRL DOCUMENT

Revenue Recognition

3 Months Ended

Mar. 31, 2019

9. Revenue Recognition

All of our product revenue consisted of sales of HEPLISAV-B in the U.S. For the three months ended March 31, 2019 and 2018, our three largest Customers represented approximately 66% and 86% of our product revenue, respectively. The following table summarizes balances and activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2019 (in thousands):

	Chargebacks, distribution fees, discounts and other fees			Returns			Total
Balance at December 31, 2018	$	1,736		$	569		$	2,305
Provision related to current period sales		3,080			458			3,538
Credit or payments made during the period		(1,658	)		(86	)		(1,744	)
Balance at March 31, 2019	$	3,158		$	941		$	4,099

Reserves for chargebacks and discounts totaling $2.3 million were recorded as reductions of accounts receivable at March 31, 2019. The remaining reserves balances totaling $1.8 million were recorded as accrued liabilities at March 31, 2019.